Skip to main content

BVF Inc

13F filer · CIK 0001056807
Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$3.91BU.S. long equity reported on 13F
Positions445 new · 2 closed
Net flow last quarter-$50.1MBuys minus sells
Top 10 positions weight65.6%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202644 positions
RVMDRevolution Medicines, Inc.$555M14.20%1.38%+3.8%Q1 2020
KYMRKymera Therapeutics, Inc.$444M11.35%4.68%-29.6%Q3 2020
XOMAXOMA Royalty Corp$323M8.25%60.55%+193.1%Q4 2016
MLTXMoonLake Immunotherapeutics$312M7.97%21.74%Not reportedQ2 2022
GHRSGH Research PLC$233M5.95%13.95%Not reportedQ2 2021
GPCRStructure Therapeutics Inc.$181M4.62%1.58%-2.7%Q1 2023
NKTRNektar Therapeutics$167M4.27%11.73%-6.6%Q3 2025
MIRMMirum Pharmaceuticals, Inc.$124M3.16%1.63%-33.4%Q3 2021
XNCRXencor Inc$115M2.94%9.60%Not reportedQ4 2013
ALKSAlkermes plc.$113M2.89%1.29%+7.7%Q1 2026
GLUEMonte Rosa Therapeutics, Inc.$108M2.76%5.23%Not reportedQ4 2024
CGEMCullinan Therapeutics, Inc.$105M2.68%8.94%Not reportedQ1 2021
PVLAPalvella Therapeutics, Inc.$103M2.63%4.67%-30.0%Q4 2024
ZYMEZymeworks Inc.$95.4M2.44%5.11%-2.3%Q2 2018
KURAKura Oncology, Inc.$92.7M2.37%9.49%Not reportedQ3 2017
IRONDisc Medicine, Inc.$84.4M2.16%3.01%-9.3%Q4 2025
STOKStoke Therapeutics, Inc.$83.4M2.13%4.08%Not reportedQ3 2025
OLMAOlema Pharmaceuticals, Inc.$66.3M1.69%6.06%Not reportedQ4 2020
ANNXAnnexon, Inc.$49.7M1.27%5.82%Not reportedQ2 2022
CBIOCrescent Biopharma, Inc.$49.5M1.27%9.90%Not reportedQ2 2025
ACIUAC Immune SA$47.2M1.21%19.48%Not reportedQ3 2018
TYRATyra Biosciences, Inc.$47.1M1.21%2.47%-25.3%Q3 2021
STROSutro Biopharma, Inc.$41.6M1.06%7.55%Not reportedQ3 2019
IMCRImmunocore Holdings plc$41.1M1.05%2.51%Not reportedQ2 2025
AVTXAvalo Therapeutics, Inc.$38.4M0.98%3.92%+27.1%Q3 2024
FDMT4D Molecular Therapeutics, Inc.$38.3M0.98%5.21%Not reportedQ4 2020
QTTBQ32 Bio Inc.$29.9M0.77%9.90%NewQ2 2026
AVRAnteris Technologies Global Corp.$29.6M0.76%3.08%Not reportedQ1 2026
FHTXFoghorn Therapeutics Inc.$28.5M0.73%9.95%Not reportedQ2 2024
ABSIAbsci Corp$27.4M0.70%1.51%NewQ2 2026
ELDNEledon Pharmaceuticals, Inc.$24.8M0.63%7.78%Not reportedQ1 2021
IVVDInvivyd, Inc.$24.6M0.63%9.56%+44.3%Q4 2025
SGMTSagimet Biosciences Inc.$19.3M0.49%8.15%NewQ2 2026
OKUROnKure Therapeutics, Inc.$14.8M0.38%8.01%+63.5%Q1 2026
IMUXImmunic, Inc.$11.8M0.30%5.61%0.0%Q4 2022
XFORX4 Pharmaceuticals, Inc$10.4M0.27%2.32%Not reportedQ2 2019
IMAImageneBio, Inc.$6.55M0.17%9.84%Not reportedQ3 2025
TCRXTScan Therapeutics, Inc.$5.45M0.14%23.21%Not reportedQ2 2023
RACCResearch Alliance Corp III$5.35M0.14%Not reportedNewQ2 2026
MOLNMolecular Partners AG$5.15M0.13%3.35%Not reportedQ3 2021
TENXTenax Therapeutics, Inc.$4.94M0.13%1.06%Not reportedQ3 2024
ENTXEntera Bio Ltd.$4.29M0.11%4.92%NewQ2 2026
IVAInventiva S.A.$2.59M0.07%0.36%Not reportedQ1 2021
ENGNWenGene Therapeutics Inc.$274K0.01%Not reportedNot reportedQ4 2023
Q1 2026Reported May 15, 202641 positions
KYMRKymera Therapeutics, Inc.$458M14.60%6.70%Not reportedQ3 2020
MLTXMoonLake Immunotherapeutics$298M9.50%30.36%-19.0%Q2 2022
RVMDRevolution Medicines, Inc.$278M8.85%1.43%-14.9%Q1 2020
NKTRNektar Therapeutics$184M5.87%12.56%+64.1%Q3 2025
GPCRStructure Therapeutics Inc.$167M5.31%1.62%-0.6%Q1 2023
MIRMMirum Pharmaceuticals, Inc.$146M4.66%2.60%+6.0%Q3 2021
GHRSGH Research PLC$122M3.87%13.95%-2.0%Q2 2021
PVLAPalvella Therapeutics, Inc.$120M3.82%6.71%+9.3%Q4 2024
ZYMEZymeworks Inc.$93.5M2.98%5.11%-5.2%Q2 2018
XNCRXencor Inc$86M2.74%9.63%Not reportedQ4 2013
STOKStoke Therapeutics, Inc.$82.9M2.64%4.09%+12.4%Q3 2025
CGEMCullinan Therapeutics, Inc.$81.7M2.60%9.36%Not reportedQ1 2021
IRONDisc Medicine, Inc.$81.4M2.59%3.33%+95.7%Q4 2025
XOMAXOMA Royalty Corp$81.3M2.59%21.75%Not reportedQ4 2016
OLMAOlema Pharmaceuticals, Inc.$79M2.52%6.06%Not reportedQ4 2020
TYRATyra Biosciences, Inc.$75.7M2.41%3.32%-7.1%Q3 2021
GLUEMonte Rosa Therapeutics, Inc.$73.4M2.34%5.29%+16.3%Q4 2024
ALKSAlkermes plc.$70.7M2.25%1.20%NewQ1 2026
KURAKura Oncology, Inc.$68.7M2.19%9.52%-2.0%Q3 2017
ACIUAC Immune SA$54.5M1.74%19.48%Not reportedQ3 2018
CBIOCrescent Biopharma, Inc.$50.5M1.61%9.97%Not reportedQ2 2025
ANNXAnnexon, Inc.$48.2M1.54%5.82%-4.7%Q2 2022
CMPXCompass Therapeutics, Inc.$41.1M1.31%4.31%Not reportedQ3 2025
IMCRImmunocore Holdings plc$39M1.24%2.55%-13.1%Q2 2025
SEPNSepterna, Inc.$32.5M1.04%3.01%-21.4%Q4 2024
STROSutro Biopharma, Inc.$31.2M0.99%7.56%Not reportedQ3 2019
FHTXFoghorn Therapeutics Inc.$27.9M0.89%9.95%+10.2%Q2 2024
FDMT4D Molecular Therapeutics, Inc.$26.8M0.85%5.51%-37.8%Q4 2020
IVVDInvivyd, Inc.$25.4M0.81%6.90%Not reportedQ4 2025
AVTXAvalo Therapeutics, Inc.$24.4M0.78%6.63%+20.5%Q3 2024
ELDNEledon Pharmaceuticals, Inc.$19.4M0.62%8.30%Not reportedQ1 2021
AVRAnteris Technologies Global Corp.$16.7M0.53%3.09%NewQ1 2026
XFORX4 Pharmaceuticals, Inc$9.23M0.29%2.37%Not reportedQ2 2019
IMUXImmunic, Inc.$8.49M0.27%56.18%Not reportedQ4 2022
OKUROnKure Therapeutics, Inc.$8.19M0.26%14.47%NewQ1 2026
TCRXTScan Therapeutics, Inc.$5.62M0.18%23.21%+6.5%Q2 2023
IMAImageneBio, Inc.$5.55M0.18%9.93%+38.4%Q3 2025
TENXTenax Therapeutics, Inc.$5.43M0.17%1.40%Not reportedQ3 2024
MOLNMolecular Partners AG$5.36M0.17%3.35%Not reportedQ3 2021
IVAInventiva S.A.$3.81M0.12%0.36%Not reportedQ1 2021
ENGNWenGene Therapeutics Inc.$2.49M0.08%Not reportedNot reportedQ4 2023
Q4 2025Reported Feb 17, 202641 positions
KYMRKymera Therapeutics, Inc.$428M14.41%6.77%Not reportedQ3 2020
RVMDRevolution Medicines, Inc.$267M9.00%1.70%-15.6%Q1 2020
MLTXMoonLake Immunotherapeutics$260M8.76%37.48%Not reportedQ2 2022
GPCRStructure Therapeutics Inc.$242M8.15%1.64%+8.6%Q1 2023
OLMAOlema Pharmaceuticals, Inc.$132M4.46%6.51%Not reportedQ4 2020
MIRMMirum Pharmaceuticals, Inc.$118M3.98%2.88%Not reportedQ3 2021
GHRSGH Research PLC$112M3.77%14.23%Not reportedQ2 2021
XNCRXencor Inc$109M3.68%9.93%+160.3%Q4 2013
ZYMEZymeworks Inc.$104M3.49%5.28%Not reportedQ2 2018
PVLAPalvella Therapeutics, Inc.$92M3.10%7.10%-24.3%Q4 2024
KURAKura Oncology, Inc.$89.5M3.01%9.81%Not reportedQ3 2017
STOKStoke Therapeutics, Inc.$71.9M2.42%3.85%+36.7%Q3 2025
XOMAXOMA Royalty Corp$68.9M2.32%21.84%Not reportedQ4 2016
ABVXAbivax S.A.$68.5M2.31%0.65%-9.0%Q3 2025
NKTRNektar Therapeutics$65.9M2.22%7.65%+22.2%Q3 2025
ACIUAC Immune SA$62.2M2.10%19.48%Not reportedQ3 2018
GLUEMonte Rosa Therapeutics, Inc.$60.1M2.02%5.85%-32.2%Q4 2024
CGEMCullinan Therapeutics, Inc.$59.5M2.00%9.55%Not reportedQ1 2021
TYRATyra Biosciences, Inc.$55.9M1.88%3.96%-41.7%Q3 2021
IRONDisc Medicine, Inc.$51.6M1.74%1.72%NewQ4 2025
IMCRImmunocore Holdings plc$50.3M1.69%2.94%-5.4%Q2 2025
IVVDInvivyd, Inc.$48.2M1.62%6.92%NewQ4 2025
SEPNSepterna, Inc.$48M1.61%3.84%-57.2%Q4 2024
ANNXAnnexon, Inc.$45.8M1.54%6.11%+30.4%Q2 2022
CMPXCompass Therapeutics, Inc.$41.7M1.40%4.35%+63.5%Q3 2025
FDMT4D Molecular Therapeutics, Inc.$34.7M1.17%8.04%Not reportedQ4 2020
CBIOCrescent Biopharma, Inc.$32.6M1.10%9.97%+98.1%Q2 2025
FHTXFoghorn Therapeutics Inc.$28.6M0.96%9.36%Not reportedQ2 2024
RPTXRepare Therapeutics Inc.$26.9M0.90%24.04%Not reportedQ2 2020
AVTXAvalo Therapeutics, Inc.$24.6M0.83%7.32%0.0%Q3 2024
PEPGPepGen Inc.$12.5M0.42%2.78%Not reportedQ3 2025
ELDNEledon Pharmaceuticals, Inc.$9.5M0.32%8.34%Not reportedQ1 2021
XFORX4 Pharmaceuticals, Inc$8.93M0.30%2.46%Not reportedQ2 2019
AXSMAxsome Therapeutics, Inc.$8.36M0.28%0.09%-90.6%Q4 2022
MOLNMolecular Partners AG$5.82M0.20%3.35%Not reportedQ3 2021
IMAImageneBio, Inc.$5.53M0.19%7.17%Not reportedQ3 2025
TCRXTScan Therapeutics, Inc.$5.23M0.18%21.80%Not reportedQ2 2023
TENXTenax Therapeutics, Inc.$4.14M0.14%3.65%Not reportedQ3 2024
IMUXImmunic, Inc.$4.08M0.14%63.57%Not reportedQ4 2022
IVAInventiva S.A.$3.19M0.11%0.36%Not reportedQ1 2021
ENGNWenGene Therapeutics Inc.$2.4M0.08%Not reportedNot reportedQ4 2023
Q3 2025Reported Nov 14, 202544 positions
KYMRKymera Therapeutics, Inc.$311M12.63%7.67%Not reportedQ3 2020
RVMDRevolution Medicines, Inc.$186M7.52%2.10%-20.2%Q1 2020
PTGXProtagonist Therapeutics, Inc$170M6.90%4.10%-20.3%Q3 2016
MLTXMoonLake Immunotherapeutics$142M5.74%37.48%Not reportedQ2 2022
CDTXCidara Therapeutics, Inc.$135M5.49%4.82%+79.8%Q2 2018
GHRSGH Research PLC$126M5.12%16.97%Not reportedQ2 2021
MIRMMirum Pharmaceuticals, Inc.$110M4.44%2.91%-45.9%Q3 2021
XOMAXOMA Royalty Corp$99.8M4.05%21.04%Not reportedQ4 2016
GPCRStructure Therapeutics Inc.$89.7M3.64%1.76%+80.9%Q1 2023
KURAKura Oncology, Inc.$76.3M3.09%9.90%+11.1%Q3 2017
SEPNSepterna, Inc.$75.5M3.06%9.00%-8.7%Q4 2024
PVLAPalvella Therapeutics, Inc.$72.8M2.95%10.47%+66.7%Q4 2024
NKTRNektar Therapeutics$72.6M2.94%6.50%NewQ3 2025
ZYMEZymeworks Inc.$67.3M2.73%5.24%-8.6%Q2 2018
AXSMAxsome Therapeutics, Inc.$59.1M2.40%0.97%-71.2%Q4 2022
ACIUAC Immune SA$57.3M2.32%19.74%Not reportedQ3 2018
IMCRImmunocore Holdings plc$57.2M2.32%3.12%+53.7%Q2 2025
OLMAOlema Pharmaceuticals, Inc.$51.8M2.10%7.71%Not reportedQ4 2020
TYRATyra Biosciences, Inc.$51.1M2.07%6.85%-7.5%Q3 2021
ABVXAbivax S.A.$47.4M1.92%0.88%NewQ3 2025
GLUEMonte Rosa Therapeutics, Inc.$41.9M1.70%9.16%Not reportedQ4 2024
FDMT4D Molecular Therapeutics, Inc.$40.2M1.63%9.90%Not reportedQ4 2020
STOKStoke Therapeutics, Inc.$38.9M1.58%3.01%NewQ3 2025
CGEMCullinan Therapeutics, Inc.$34.1M1.38%9.73%Not reportedQ1 2021
CELCCelcuity Inc.$32.5M1.32%1.52%-81.0%Q2 2024
XNCRXencor Inc$32.1M1.30%3.84%Not reportedQ4 2013
FHTXFoghorn Therapeutics Inc.$25.9M1.05%9.38%Not reportedQ2 2024
ANNXAnnexon, Inc.$21.4M0.87%6.40%Not reportedQ2 2022
RPTXRepare Therapeutics Inc.$18.2M0.74%24.04%Not reportedQ2 2020
AVTXAvalo Therapeutics, Inc.$17.2M0.70%7.60%+31.8%Q3 2024
CMPXCompass Therapeutics, Inc.$16.6M0.67%2.68%NewQ3 2025
CBIOCrescent Biopharma, Inc.$16.5M0.67%9.99%Not reportedQ2 2025
ELDNEledon Pharmaceuticals, Inc.$16.3M0.66%10.51%Not reportedQ1 2021
TCRXTScan Therapeutics, Inc.$9.51M0.39%21.80%Not reportedQ2 2023
PEPGPepGen Inc.$8.85M0.36%5.84%NewQ3 2025
XFORX4 Pharmaceuticals, Inc$7.64M0.31%8.88%Not reportedQ2 2019
IMUXImmunic, Inc.$6.75M0.27%7.76%Not reportedQ4 2022
IMAImageneBio, Inc.$6.54M0.26%19.95%NewQ3 2025
MOLNMolecular Partners AG$5.02M0.20%3.35%Not reportedQ3 2021
IVAInventiva S.A.$3.97M0.16%0.72%Not reportedQ1 2021
TENXTenax Therapeutics, Inc.$2.58M0.10%5.75%Not reportedQ3 2024
SABSSAB Biotherapeutics, Inc.$1.87M0.08%1.96%+1.6%Q4 2023
FBRXForte Biosciences, Inc.$980K0.04%0.52%-88.9%Q2 2020
ENGNWenGene Therapeutics Inc.$681K0.03%Not reportedNot reportedQ4 2023
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.